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To my lovely Faranak
Without health life is not life; it is only a state of languor and suffering
-an image of death.
-Buddha-

Abstract
This thesis presents the design and optimisation of a microwave hyperthermia
antenna system for treatment of head and neck cancer as well as brain cancer. Hy-
perthermia (HT) has shown the ability to enhance the performance of radiotherapy
and chemotherapy in many clinical trials. The incidence of increased tissue toxi-
city as a result of high radiotherapy dose has made hyperthermia a safe adjuvant
treatment to radiotherapy.
Although many clinical studies have shown the effectiveness of hyperthermia
for treatment of head and neck (H&N) cancer, the presence of large vessels, tissue
transitions and critical tissues in the head and neck poses therapeutic challenges
for treatment of advanced tumours in this region. Late side-effects of conventional
therapies in treatment of brain tumours in children have made hyperthermia an
attractive method. However, heating tumours in the brain is even more challenging
due to the brain’s high levels of sensitivity, thermal conductivity and perfusion.
This thesis presents microwave hyperthermia applicators as an efficient means
to heat H&N and brain tumours. An ultra-wideband antenna, as the radiating el-
ement in microwave hyperthermia applicators, has therefore been designed, built
and evaluated. The time-reversal focusing technique is used to target electromag-
netic energy into the tumour. The effect of frequency and virtual source positions
in the time-reversal method are studied, for different tumour sizes and positions,
so as to obtain more accurate treatment planning. The optimal detailed design
of the applicator, such as the number of antennae and their positions, are also
investigated.
The second part of this thesis focuses on applicators for the treatment of brain
tumours in children. Helmet applicators are presented and there is an investi-
gation into how the number of antennae and their frequencies affects applicator’s
performance when heating large, deep-seated brain tumours. Finally, the optimum
position of antennae in helmet applicators is discovered by running optimisations
on simplified and realistic models of a child’s head.
Keywords: microwave hyperthermia, time reversal, wideband antenna, treat-
i
ment planning, head and neck tumours.
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CHAPTER 1
Introduction
Cancer is the uncontrolled growth of abnormal cells in the body. There are more
than 100 types of cancer and each is classified by the type of cell that is initially in-
volved. In a normal process, human cells grow and divide to form new cells while
the old cells die. However, when cancer develops this process breaks down. The
old and damaged cells survive and new and unnecessary cells form.. These new
cells can continue to grow and form masses of tissue called tumours. Malignant
tumours form when cancerous cells move around the body, destroying healthy
tissues. When cancer cells spread to other parts of the body, invading and destroy-
ing healthy tissues, They are said to have metastasised. This process is called
metastasis and the outcome is a serious and life-threatening condition [1, 2].
Cancer is among the leading causes of death worldwide. 14 million new cases
were reported in 2012 and 8.8 million cancer-related deaths worldwide in 2015
[3]. The uncontrolled growth of cancerous cells can affect any part of the body.
The resulting growth invades surrounding tissues and can metastasise to remote
areas of the body. Although the death rate from cancer continues to decay, cancer
still remains a major health problem affecting more than 1.6 million people each
year [4]. According to World Health Organization, 30-50% of all cancers could
be prevented by avoiding the main risk factors such as tobacco and alcohol and by
exercising regularly and maintaining a healthy lifestyle [3].
The standard cancer treatment methods include surgery, radiotherapy, and
chemotherapy. These treatments may be used alone or in combination with other
methods. The choice of therapy may depend upon the location and stage of the
cancer and the general condition of the patient. Surgery is the longest-standing
therapy for cancer and is usually combined with other modalities to improve the
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treatment of tumours. This is because in many patients, simply excising a tumour
is not sufficient to prevent a relapse. Radiotherapy, on the other hand, is not very
effective in lower doses and can fail to treat bulky tumours. Moreover, the lim-
ited dose tolerance of some normal tissues can put the patient at risk. This means
the admissible dose has to be limited and so treatment of the tumour may fail.
This treatment modality may also lead to late complications and increased risk
of developing secondary cancers. Chemotherapy utilises one or more anti-cancer
drugs. The efficacy of chemotherapy is dependent on the type and stage of can-
cer. Chemotherapy may eradicate cancer if administered in the early stages of the
disease when the metastasis is undetectable [5].
1.1 Hyperthermia
The disappearance of a tumour after high fever was first reported over a cen-
tury ago [6]. Since the 1960s, hyperthermia has attracted considerable interest
as a cancer therapy. In hyperthermia treatment tumours are heated selectively to
temperatures above 40◦C while healthy tissues are kept below tissue-dependent
critical temperatures [7]. The rationale for using hyperthermia is that treatment
at temperatures between 40 and 44◦C is cytotoxic for cells in an environment
with low pO2 and low pH. These conditions are found in tumour tissues with low
blood perfusion. Under these conditions, radiotherapy is less effective and cyto-
toxic agents reach tumour areas in lower concentrations [8]. Since hyperthermia
increases tumour blood flow, it increases the oxygenation of hypoxic tumours and
therefore acts a radiosensitizer of the tumour [9]. Increased blood flow also leads
to greater uptake of cytotoxic agents and enhances the efficacy of chemotherapy
[10][11].
In a recent work by Issel et al., [12], six important features of hyperthermia
have been proposed which are representing the effect of this modality to prevent
tumour growth. As shown in Figure 1.1, the first effect is ‘blocking cell survival’.
This is based on the capability of heat to kill cells, in a correlation between time
and temperature dosage. At the same time, heat can lead to thermotolerance in
some surviving cells. The second effect of hyperthermia is ‘inducing cellular
stress response’ in terms of heat-shock proteins. Heat-shock proteins are pro-
duced by cells when they are exposed to temperatures higher than normal body
temperature. These proteins assist in recovery from stress by repairing damaged
proteins or by impairing them. The third effect is ‘modulation of immune re-
sponse’. The release of heat-shock proteins carrying tumour antigens, the thermal
activation of immunocompetent cells and the effects of heat on lymphocytes mov-
ing into the tumour are all involved in regulating the immune system. The fourth
effect of hyperthermia is ‘changing tumour microenvironment’. This covers the
2
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physiological changes resulting from heat, the effects on tumour vasculature and
the metabolic transformations. The last two effects of heat are ‘evading DNA
repair’ and ‘sensitization to radiation and chemotherapy’. The effect of hyper-
thermia on DNA repair has shown itself in radio-sensitization of the cells, that
are deficient in repairing of DNA double-strand breaks through the homologous
recombination (HRR) or non-homologous end-joining (NHEJ) repair pathways.
Hyperthermia inhibits the HRR pathway after application of heat over a period of
time. This provides a justification for developing anti-cancer treatments combin-
ing hyperthermia-induced HRR inhibition in tumours, with systematic application
of drugs for local sensitisation of cancer cells to the DNA-damaging agents.
Figure 1.1: The Hallmarks of hyperthermia according to [12].
In a proposed thermal-dose relationship, it was shown that for every 1◦C rise
in temperature above 43◦C, cell killing doubles while cell killing diminishes by
about one quarter for every 1◦C below 43◦C [13]. A method was presented that
combines time and temperature to a so-called thermal isoeffective dose. This re-
sulted in the expressions CEM43 and CEM43T90 which can be used to compare
different tissues in terms of their thermal-dose sensitivity. A review paper by
Gerard C. van Rhoon [14] discusses the relevance of CEM43 as a thermal-dose
parameter for monitoring hyperthermia treatment. The paper mentions a number
of weaknesses in the CEM43 concept, when used to predict the effectiveness of ra-
diotherapy combined with hyperthermia. The effect of sensitisation by enhanced
oxygenation, multiple fractions and variation in interval time have not been in-
cluded in the concept of CEM43. The paper proposes that further research be
carried out in the field of CEM43, to detect any thermal dose-effect correlation.
3
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Clinical trials (research studies involving people) evaluate the advantages of
different treatments and broaden the options available to patients. Numerous clin-
ical trials have demonstrated the beneficial effect of hyperthermia in treating dif-
ferent tumour sites, when incorporated into standard radiotherapy and chemother-
apy protocols [15][16]. All these studies show that adding hyperthermia makes
tumour cells more sensitive to chemo or radiotherapy and thus positively affects
treatment outcome. Several clinical trials have compared radiotherapy alone with
combined thermoradiotherapy. These have demonstrated the benefits of hyper-
thermia for local control and survival in recurrent breast cancer, cervical carci-
noma or H&N tumours [17][18][19][20]. Moreover, many clinical study reviews
have shown the capabilities of hyperthermia to enhance cell sensitivity to radi-
ation and drugs [22][23][8][17]. In 1997, Amichetti showed the advantages of
local hyperthermia combined with radiotherapy in treating advanced squamous
cell carcinoma of the head and neck (H&N). Except for mild local toxicity, no se-
vere late side effects were observed in this study [24]. The respective benefits of
adding hyperthermia to standard radiotherapy for patients with locally advanced
cervical carcinoma and pelvic tumours were also shown in separate studies by
Franckena et al. and Van der Zee et al. [25][26]. In the first randomised phase 3
trial by Issels et al, regional hyperthermia has been shown to increase the benefits
of chemotherapy in localized high-risk soft-tissue sarcoma [27].
1.1.1 Hyperthermia in head and neck cancer
5% of all patients suffering from cancer worldwide have tumours in H&N region
[28]. Annually, of 550,000 cases of H&N cancer, 300,000 cases of deaths occur.
The number of males with this type of cancer is 2-4 times greater than the num-
ber of females. For H&N cancer, the most important risk factors are alcohol and
tobacco consumption. Incidence of this type of cancer from infection with car-
cinogenic types of human papilloma virus (HPV) is also increasing. H&N cancers
originate in the upper airways and swallowing tracts and are further categorized
by the areas of the head or neck in which they begin. These areas, shown in Fig-
ure 1.2, are: oral cavity, pharynx, larynx, paranasal sinuses and nasal cavity and
salivary glands. These cancers are the sixth most prominent cancers worldwide
[3].
Management of advanced H&N cancer is challenging. For locally advanced
H&N cancer, the results of phase II and III studies have shown the best standard
treatment to be radiation combined with chemotherapy, albeit with added toxicity.
In the treatment of these tumours, standard radiochemotherapy and chemoradio-
therpay generally result in a five-year survival rate of 20-65%. This depends on
the stage and location of cancer [29]. Other studies show that combined radio-
therapy and chemotherapy in H&N results in an 8% increase in two-year survival.
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More recently, a 4.5% increase in five-year survival has been reported [31][32].
Although survival has somewhat improved and complete response and local con-
trol in combined-modality treatments are typically high, the toxicity level in this
type of tumour is severe and increases with radiotherapy doses. More than 80%
of patients experience severe toxicity with current treatment methods. Increas-
ing swallowing difficulties and decreasing saliva production have been observed
in high radiation doses, which can lead to problems in speaking and eating. So,
the aim should be to decrease the toxicity and increase the effectiveness of H&N
cancer treatments.
Figure 1.2: Head and neck cancer regions [1]
Enhancement in treatment outcomes of H&N cancer can be expected from
combination of hyperthermia and radiotherapy. This enhancement results from
an increased RT dose in the tumour and decreased RT dose in the areas at risk.
In early studies by Valdagni et al., long-term follow-up of a randomised trial was
used to compare radiotherapy alone versus RT plus hyperthermia, when used in
metastatic lymph nodes in H&N patients. The five-year follow-up confirmed the
effectiveness of combined RT and hyperthermia and also the absence of toxicity in
the treatment [33][34]. Recent meta-analysis by Data et al. [16], has summarized
the outcome of clinical trials in H&N cancers (HNCs) using hyperthermia and
radiotherapy versus radiotherapy alone. The conclusion was that hyperthermia
combined with radiotherapy enhances the probability of the complete response in
H&N cancers by around 25% compared to radiotherapy alone.
Figure 1.3 shows a summary of the results of phase III randomised trials for
H&N cancers. These results show a clear benefit in adding hyperthermia to stan-
dard treatment regimens [20]. In the first study, superficially located metastatic
lymph nodes from the H&N received RT or RT combined with hyperthermia
5
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(HT). The results of the treatments showed a complete response rate of 82.3%
after RT+HT, versus 36.8% after RT alone. In the second study, advanced tu-
mours mostly close to the skin were treated either by HT combined with RT, or
RT alone. The results of RT+HT treatment showed significantly improved tu-
mour control in patients with advanced tumours. In the third study, tumours in the
oropharynx, hypopharynx and oral cavity were given RT or RT+HT. The complete
response rate in the group with RT alone was 42.4%, whilst the HT group was on
78.6%. In the fourth study, patients with nasopharyngeal cancer were treated with
chemo-radiotherapy, with or without HT. The study results showed a significant
improvement in the control response: i.e. 81.1% (CRT) to 95.6% (CRT + HT).
In the final study, nasopharyngeal cancer was given CRT with or without HT.
The 36-month survival rate for CRT was 54% compared to 73% for CRT+HT. In
addition to these clinical trials, early experiences with the HYPERcollar3D appli-
cator were recently reported, based on the treatment of five patients with H&N
tumours [21]. In these experiments, radiotherapy was followed by hyperthermia
sessions once a week and invasive thermometry used, when possible, to monitor
the temperature.
Different heating techniques were used in these studies. In the first study,
the radiative heating was conducted in the range of 280-300 MHz using the BSD
1000 system. In the second study, capacitive heating at 27.12 KHz was applied
using the Siemens Ultraterm 607E diathermia machine. In the third study, HT was
applied at 8 MHz using a capacitive applicator. However, investigating the per-
formance of the applicator showed that the applicator was not able to treat deeply
located tumours. In the fourth study, a wire-based conductive heating method at
915 MHz was used to heat tumours. In the final study, hyperthermia was delivered
by a capacitive applicator at 13.56 MHz or 40.68 MHz. The results of all these
studies indicated improvements in radiotherapy and chemotherapy by adding hy-
perthermia and with no toxicity caused. However the applicators concerned were
only able to heat superficial tumours and not deeply located ones. Moreover, mon-
itoring and control of the temperature in all of these trials was limited which made
it difficult to evaluate the required thermal dose. All of these results necessitate
the design and development of applicators with deep-heating capability. Chap-
ter 2 contains a more detailed discussion of the requirements for designing and
developing a hyperthermia applicator with deep-heating capability for the H&N.
1.1.2 Hyperthermia and childhood brain cancer
Although there has been a considerable improvement in the treatment of can-
cer in general, brain cancer treatments often give disappointing results. In two
decades, conventional treatment methods have failed to control tumour progres-
sion [35][36]. Of the main types of brain tumour, glioblastoma is the most com-
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Figure 1.3: Results of phase III randomised trials on hyperthermia for H&N can-
cers [20].
mon and most fatal in adults, usually relapsing very soon after surgery. The av-
erage survival for patients with malignant glioma is only 17 weeks; this can be
extended to 30 weeks after surgery and chemotherapy [37].
Studies of cancer incidences in children younger than 15 years old have shown
brain tumours to be the second most common cancer, representing 20-30% of all
childhood cancers. Medulloblastoma is the most common type of pediatric brain
tumour. Treatments for this tumour begin with surgical excision. The addition of
radiotherapy and chemotherapy may increase the disease-free survival rate. How-
ever, there are side effects from radiation treatments including cognitive damage,
problems in bone growth and hearing loss [38]. Every year, 300 children in Swe-
den develop a malignancy, one third of which are brain tumours. While modern
cancer therapies cure 75% of all paediatric cancer cases, these therapies (like ra-
diotherapy) have been reported as having long-lasting side effects. Side-effects
include intellectual impairment and perturbations in growth and puberty[39, 40].
Hyperthermia is a safe treatment, with a slow heating process and minimal
damage to the surrounding normal tissue. Experiences with hyperthermia in treat-
ment of brain tumours are limited to glioblastoma multiforme in adults. Intersti-
tial hyperthermia combined with brachytherapy has been demonstrated as safe for
this type of tumour, with no additional toxic effects [41, 42]. It was subsequently
demonstrated that interstitial brain HT given before and after brachytherapy and
after radiotherapy significantly improved survival of high-grade glioblastoma pa-
tients, with acceptable levels of toxicity [43]. Despite the improved treatment
outcome, it was difficult to achieve the homogeneous therapeutic temperatures
sought. Figure 1.4 shows how interstitial electrodes are implanted in a brain tu-
7
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mour. In a recent study, a group of patients with malignant glioma was treated with
hyperthermia in combination with radiotherapy and chemotherapy. In the study,
hyperthermia was applied using a radio-frequency applicator at 13.56 MHz. An-
other group of patients underwent conventional radiotherapy and chemotherapy.
An evaluation of the patients three months post-treatment showed glioma growth
suspension and decreased tumour diameter in the hyperthermia group [44].
Figure 1.4: Electrodes implanted in a brain tumour [45].
Magnetic fluid hyperthermia (MFH) has been proposed as an alternative to
interstitial HT, as it may achieve higher temperatures in intracranial tumours. This
method was used to allow for more precise heating and its combination with a
lower radiotherapy dosage was shown to bring about a higher overall survival
rate than conventional therapies [46]. The method was shown to be safe and
effective in the treatment of recurrent glioblastoma. However, this technology
requires a direct injection of iron oxide nanoparticles dispersed in water. This
aqueous dispersion of iron-oxide is injected directly into the tumour and then
excited by alternating magnetic fields (AMF), which produces local heat in the
tumour. The AMF needs appropriate field amplitude and frequency to heat up
the particles. Magnetic nanoparticles (MNP) use various mechanisms to convert
magnetic energy into heat energy. Some of the main heat-generating mechanisms
are Ne´el and Brownian relaxations [47]. In Ne´el relaxation, heat is generated by
rapid changes in the direction of magnetic moments. Brownian relaxation results
from the physical rotation of MNPs in their host medium. Both of these frictions
lead to a phase difference between the applied magnetic field and the direction of
magnetic moment. This generates thermal loss [48]. However, these MNPs may
remain in the body for life, thus hindering any future MRI scans.
Another method which can non-invasively deliver localised energy in the brain
is high-intensity focused ultrasound (HIFU) [49, 50]. Specific transducers are
used to concentrate the acoustic energy into a small volume. Phase array applica-
tors are one such transducer. They provide electronic control over beam geometry
and direction and can be adjusted to allow optimum power deposition. To achieve
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3D control of the ultrasound beam, many small elements are placed in 2D arrays.
An acoustic focus is created by controlling the timing of the transmitted wave at
each element, so that all the waves arrive in phase at the desired location. For
hyperthermia applications, such a system delivers small volumetric sonications
from an ultrasound phased-array transmitter, destroying the intracranial lesions
by thermocoagulation [49]. Nevertheless, heating large volumes (typical in paedi-
atric brain tumours) is still demanding with present technology. Moreover, regions
of the brain close to the skull continue to be a limitation for HIFU, due to heating
of the skull [51] [52].
Although most of the patients treated with hyperthermia are adults, encourag-
ing clinical results on children and adolescents are seen, as discussed in [53]. Be-
tween 1993 and 2009, 101 patients (with a median age of 5 years 10 months) were
treated for: extracranial germ cell tumours, 45 patients; rhabdomyosarcomas, 23
patients; soft-tissue sarcomas, 10 patients; osteosarcomas and ewing sarcomas, 7
patients; intestinal tumours, 2 patients; other, 7 patients. Of these, 64 patients were
treated for a relapse of their condition and 37 for irresectable tumours with poor
response or even progress under chemotherapy. The thermo-chemo treatment fol-
lowed by surgery (61) or radiation (27) given to these unfavorable patient groups
resulted in 31 patients with complete response and 27 with partial response. Af-
ter a median follow-up of 27 months, 45 patients had no evidence of disease, 12
were living with the disease, 41 had died from the disease and three had died of
complications other than from thermo-chemotherapy. In particular, the germ-cell
tumour subgroup responded fairly well to the treatment, with five-year event-free
survival of 62% and five-year overall survival of 72% [53].
In another study by Wessalowski et al. [54], cisplatin-based chemotherapy
combined with deep regional hyperthermia was used as salvage treatment for chil-
dren and adults with refractory or recurrent malignant germ-cell tumours. Hyper-
thermia was applied with electromagnetic applicators of different dimensions, ad-
justed for infants, children and adults of different pelvic or abdominal dimensions.
Figure 1.5 shows the hyperthermia applicator used in this study for a child. This
study, which was administered with a 20% lower cisplatin dose in chemother-
apy, resulted in an objective tumour response in 86% of patients with five-year
overall survival of 72%. The clinical results of this study showed that combining
HT with chemotherapy could improve the tumour response in children and adults
with recurrent germ-cell tumours. The positive outcomes of combined treatment
modalities using hyperthermia in brain tumours raises a demand for applicators
specifically designed for heating these tumours. This becomes even more crucial
in the case of children with brain tumours, where, to date, no electromagnetic
hyperthermia applicator has been developed.
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Figure 1.5: Clinical set-up for hyperthermia of a child [55].
1.2 Aim of the thesis
The results of clinical studies for different tumour sites all show the significance of
adding hyperthermia treatment to standard therapies. However, in the H&N can-
cers, the complex geometry and the presence of large cooling vessels and highly
thermo-sensitive tissues, such as the spinal cord and the brain, makes heating more
challenging. Consequently, appropriate heating technology and temperature mea-
surement tools are required to deliver an adequate thermal dose to this region. The
hyperthermia equipment must provide a sufficient degree of freedom and enough
resolution to allow adjustment of the power absorption pattern in the tumour and
its surrounding healthy tissues. Up to now however, clinical hyperthermia has
been mostly used for heating of superficial tumours in the H&N due to the conve-
nience of heating, thermometry and clinical routines. There again, brain tumours
are even more challenging to heat due to the high degree of sensitivity, thermal
conductivity and perfusion of the brain.
The aim of this thesis is to develop hyperthermia applicators for treatment of
H&N tumours and brain tumours and optimising the performance of these ap-
plicators. There are several ways to optimise the performance of a hyperthermia
applicator. The main goal is to target electromagnetic energy into the tumour area,
creating a highly localized heating region. The more energy/power deposited into
the tumour, the higher the temperature elevation. At the same time, the temper-
ature of healthy tissues should be kept below critical levels. The main design
parameters of a hyperthermia applicator need to be determined and optimised in
order to meet all these requirements. As it is also mentioned in the work by [56],
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the important design parameters are the type, the number and the positioning of
antenna elements in applicators and the operational frequency of the treatment.
Many studies have shown that significant improvement in tumour power de-
position can be obtained by increasing the number of the antenna elements or
antenna rings [57][58]. Moreover, the frequency of operation for optimal power
density deposition depends on the size and position of the tumour and size of the
area being treated. For example, the frequency of 434 MHz was chosen in the
work by Paulides et al. [59] for treatment of H&N tumours, while 70 MHz was
the operational frequency for treatment of pelvic tumours [60][61]. Antenna char-
acteristics, such as their near-field radiation pattern, are also influential factors in
creating a localized heating zone. Finally, the optimal positioning of the antennas
in relation to each other and to the patient can lead to enhanced power deposition
in the tumour.
This thesis describes the design and development of hyperthermia applicators
for heating H&N tumours and brain tumours. While different design approaches
have been presented for the H&N applicators and the brain applicator, all the
applicators have the capability for focus-size adjustments, by adapting the power
density pattern. This is achieved by optimizing the antenna elements to have
wideband performance over the required range of frequencies. Increasing the
number of antennas and optimizing their positioning in the applicator is the other
approach we follow to achieve adequate heating in tumors. Finally, the time-
reversal focusing method is employed in hyperthermia treatment planning where
focused heating in tumours is planned.
The thesis is organized as follows: Chapter II introduces the requirements of
microwave hyperthermia systems for deep-seated tumors and reviews the simula-
tion techniques in hyperthermia treatment planning, emphasising the time-reversal
focusing technique. Brief summaries of the papers are given in Chapter III while
concluding remarks and discussions of future work are presented in Chapter IV.
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CHAPTER 2
Hyperthermia system
Different techniques are applied in clinical hyperthermia depending on the tumour
size and position. Intracavitary, interstitial and superficial heating techniques are
all included in local hyperthermia, while locoregional hyperthermia is applied to
deep-seated tumours, such as tumours of the pelvis, bladder and prostate. Most
clinical hyperthermia systems used in deep heating employ electromagnetic (EM)
fields or ultrasound (US). There are four main parts to a hyperthermia system:
treatment planning, an amplifier system, an antenna applicator and a thermometer,
Figure 2.1. The water bolus and the cooling system are also parts of the applicator.
An amplifier system is used to power the EM radiation, which is then de-
livered to the patient via an antenna applicator. An antenna is a device which
converts electrical energy into radio waves or electromagnetic radiation. Treat-
ment planning allows the distribution of power absorbed by the body to be altered
by changing the amplitude and phase of antennas in an applicator. The optimal
amplitudes and phases are obtained during the treatment planning process.
A heating device for superficial hyperthermia should be able to increase the tu-
mour temperature at a rate of 1◦C per minute, corresponding to a SAR of 60 W/Kg
in muscle, whilst allowing full regulation of the output power [62]. An applicator
for deep hyperthermia must also meet certain minimum requirements regarding
its energy distribution characteristics. The ability to focus energy distribution
and control focus size and location is needed so that higher energy deposition is
achieved in the tumour than in healthy tissue. A ratio is therefore defined, be-
tween the energy deposition in the target and the energy deposition in the healthy
tissues. This ratio must be above 1.5 for any applicator, if that applicator is to be
deemed capable of deep heating [63].
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The EM fields used to heat body tissues are in the frequency range of 0.5 MHz
to 2.45 GHz, covering low frequencies to microwave range. Different types of ap-
plicators were developed for this frequency range including waveguides, dipole
antennas and coils. In local hyperthermia where superficial tumours are treated,
different applicators are used based on the operational frequency. Capacitive elec-
trodes and inductive coils have been used at frequencies lower than 40 MHz [64].
At frequencies greater than 400 MHz, waveguide applicators, horns, spirals and
current sheets are some antennas types in clinical use. Annular-phased arrays are
the most common type of applicators for regional hyperthermia, when treating
deep-seated tumours. The most common phased array set up for deep hyper-
thermia is a circular or elliptical array of antennas arranged around the body, as
shown in Figure 2.2. The desired focusing into the target is achieved by construc-
tive interference of the radiated electromagnetic fields from the antennas [64].
The remainder of this chapter presents different types of antenna elements used in
hyperthermia phased arrays.
A water bolus, as part of the applicator, is usually placed between the anten-
nas and body surface to emit microwaves or radio waves into the tumours. The
water bolus on the body surface ensures the electromagnetic coupling to the body,
improves the impedance match to the tissue and is used as a method of cooling
skin and other superficial tissues. The interaction of the generated EM fields with
body tissues, governed by complex tissue permittivity, results in EM heating of
the tissues [5].
In hyperthermia treatment planning, a 3D patient model is created and used to
optimise the treatment parameters. This is done by electromagnetic and temper-
ature simulations and results in the temperature pattern which is the goal during
treatment [65]. The process of hyperthermia treatment planning is explained in
more detail in the following sections. Thermometry is used to measure the tem-
perature of the target during the treatment, in order to evaluate the quality of the
clinical outcome. Invasive thermometry systems consist of temperature sensors
and provide temperatures from a limited volume of the target. Among the non-
invasive thermometry methods, magnetic resonance thermometry has been clini-
cally proven as a reliable real-time temperature monitoring technique. Magnetic
resonance imaging also has a higher spatial resolution and anatomical coverage
per unit time compared to other methods including microwave imaging, computed
tomography or ultrasound [66][67].
2.1 Basic electromagnetic theory
The theory of electromagnetic fileds can be described by a set of coupled partial
differential equations well known as Maxwell’s equations [68]. They have the
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Figure 2.1: Main components of a hyperthermia system.
Figure 2.2: Conceptional design of H&N applicator.
following differential form:
∇×E = −µ ∂H
∂ t
(2.1)
∇×H = σE+ ε ∂E
∂ t
(2.2)
∇ · εE = ρ (2.3)
∇ ·µH = 0 (2.4)
where E is the electric field intensity, H is the magnetic field intensity, µ is
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permeability, σ is conductivity, ε is permittivity and ρ is electric charge density.
These four equations, together with the equation of continuity and Lorentz’s force,
can be used to explain and predict all macroscopic electromagnetic phenomena.
By combining Eqs (2.1) and (2.2), we obtain the vector wave equation for the
electric field in an inhomogeneous medium:
(∇2− 1
c2
∂ 2
∂ t2
−µσ ∂
∂ t
)E(r, t) = µ
∂J
∂ t
+
1
ε
∇ρ (2.5)
where c =
√εµ is the speed of light. The wave equation can be further sim-
plified by assuming a time-harmonic field as:
∇2E(r)− γ2E(r) = jωµJ(r)+ 1
ε
∇ρ (2.6)
where ω is the angular frequency in radians/second and γ is the propagation
constant which determines wave propagation in different lossy media:
γ2 = (α+ jβ )2 = jωµε−ω2µε (2.7)
Here, α is the attenuation constant and β the phase constant. As the wave
propagates through a medium, the amplitude of the wave is attenuated by a factor
of e−αz. The distance δ through which the amplitude of a traveling plane wave
decreases by a factor of e−1 is called the depth of penetration:
δ =
1
α
=
1√
pi fµσ
(m). (2.8)
2.2 Hyperthermia applicators
The goal of this work is to design and develop the optimum hyperthermia ap-
plicators for treatment of tumours in the H&N region and brain tumours. The
applicator is one of the main components of the hyperthermia system. It therefore
plays a major role in the delivery of EM energy into the tumour. The applicators
must be able to effectively heat superficial as well as deeply-located tumours. In
designing applicators capable of deep heating in the body, trade-offs have to be
made in terms of penetration depth, focal size and size of target. According to
hyperthermia quality guidelines for deep hyperthermia, the applicator should be
able to reach an average SAR in the tumour. This is at least 1.5 times higher than
the average SAR in healthy tissues [63].
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In capacitive heating, EM fields in the range 70-140 MHz are used, with a
large wavelength compared to the tumour and body size. The limited degree of
control over focused power density is an important challenge for these applicators.
Preferential heating of fat layers which is approximately 100 times higher than in
muscle, is also a major problem. Despite these problems, reports from clinical
experience have shown that an 8 MHz capacitive applicator raises tumour tem-
perature to 42◦C in superficial as well as deep-seated H&N and pelvic tumours,
with minimal adverse effect [69]. Phased arrays, the most common type of deep
hyperthermia applicators, were investigated in the early 1980s for HT treatment
of superficial H&N tumours [70][71]. However, HYPERcollar, a phased-array of
12 antennas, was the first applicator to be developed for deep heating in the H&N
region [72]. Recently, HYPERcollar3D has been developed by the same group,
with more focus on integrating microwave hyperthermia into the clinic [73].
In designing deep hyperthermia applicators, the number of antennas is one
of the most important factors determining the power deposition pattern in the tu-
mour and its surrounding healthy tissues [57]. Another important factor facilitat-
ing power transfer from applicator to body is a water bolus, placed between the
applicator and the patient’s body surface. High power transmission values and
low-power reflection values indicate good coupling efficiency between applicator
and patient. Figure 2.3 shows the cross section of the Chalmers H&N applica-
tor, including antennas, water bolus and a cross-section of the neck. The coming
sections will examine the pros and cons of current hyperthermia applicators, in-
cluding antenna elements and water bolus.
Figure 2.3: The Chalmers H&N applicator shown along a cross-section of the
neck.
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2.2.1 The single-antenna element
The most commonly used antennas in deep hypethermia applicators are the waveg-
uide or dipole types. They are either filled with water or immersed in it to reduce
their dimensions. Waveguides are usually filled with water, but they are large and
heavy and have narrow bandwidth [74]. AMC-4 and AMC-8 are two of the exist-
ing deep hyperthermia systems, composed of 1 ring and 2 rings of 4 waveguides
respectively, both at 70MHz. Due to the low operational frequency, these applica-
tors provide a large penetration depth, with the resulting focus size usually larger
than the size of the tumour. Recently, a multichannel phased array system has been
produced by ALBA for deep hyperthermia treatment. The ALBA 4D system was
inspired by the AMC 4/8 systems [75]. BSD2000 is a commercial deep hyper-
thermia system which uses dipole antennas as radiating elements in the frequency
range of 75-120 MHz [76]. Sigma-Eye is a modified elliptical applicator consist-
ing of 24 dipoles, arranged in three rings of eight antennas. The larger number of
antennas in this applicator compared to its predecessor (the Sigma-60) has led to
higher thermal dose in the tumour [77]. A more recent version of Sigma-Eye is
compatible with magnetic resonance imaging and allows MR scans of the patient
and noninvasive monitoring of deep tissue temperature [78]. However, the draw-
back of dipoles is the high level of power absorption resulting from their matching
networks. Moreover, the omnidirectional pattern of dipole antennas makes them
more prone to cross-coupling effects [79].
Patch antennas have attracted a lot of attention for use in hyperthermia, due
to their low weight and because there is no need for matching networks, Figure
2.4. A probe-fed patch antenna has been designed for HYPERcollar and HYPER-
collar3D phased-array applicators, which operates at 433MHz [80]. The antenna
with a bandwidth of 20 MHz and a reflection coefficient ≤ -15 dB delivered effi-
cient power coupling into the water bolus by using water as a substrate material.
In a study by our group, a patch antenna of about 170 MHz bandwidth was de-
signed for a wideband hyperthermia system, Figure 2.4(d). Triangular in shape,
this patch antenna was excited using a probe feed and immersed in a water bolus
to decrease its operating frequency. Analysis of the single antenna showed a wide-
band performance beyond its bandwidth, but only by using water boli of different
permittivities; something that was not optimal for clinical practice [81]. The de-
sired bandwidth of 750 MHz was achieved later by the stacked φ -slot design with
two shorting pins, but the radiation pattern split above 750 MHz, which was not
desirable [82].
In a recent study by Winter et al, a hybrid radiofrequency applicator support-
ing magnetic resonance imaging and MR-controlled targeted RF heating was de-
signed and evaluated at ultra-high magnetic fields [83]. The antennas used in this
hybrid applicator were dipole Bow-Tie antennas immersed in distilled water to
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shrink their effective length. The building block of the Bow-Tie antenna had a
dimension of 156 × 70 × 68 mm3 resulting in a 3dB bandwidth of 143 MHz at
the excitation frequency of 298 MHz. In this thesis, modified Bow-Tie antennas
are presented as the antenna elements used in the hyperthermia applicators. The
characteristics of this single Bow-Tie (SGBT) antenna are compared with those of
dipole, patch, waveguide and the recently-used Bow-Tie antennas and are given
in Table 2.1.
(a) (b)
(c) (d)
Figure 2.4: Antenna elements for hyperthermia applicators, (a) Waveguide an-
tenna (b) Dipole antenna (c) Patch antennas in a two-ring measure-
ment set-up [80] (d) Triangular patch antenna [81].
2.2.2 Water bolus
Water bolus is an important part of hyperthermia applicators and has a profound
effect on the heating pattern of the antennas. In most cases, the space between the
applicator and the patient is filled with water to improve coupling into the patient
and reduce stray fields. Furthermore, the surface temperature can be controlled
by circulating the water at low temperature. The water is typically encased in
plastic bags in a closed water bolus system. The efficiency of the power coupling
between applicator and patient can be changed by varying the thickness and shape
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Table 2.1: Typical characteristics of different antennas in a hyperthermia appli-
cator. In the table RP = radiation pattern, BW = bandwidth, Di = di-
rectional, OmDi = omni-directional, SemDi = semi-directional, MC =
matching circuit, AP = aperture size, Pol = polarization, Dim = dimen-
sion.
Waveguide Dipole Patch Bow-Tie SGBT Desired
in [83] antenna
S11 <-25 dB <-10 dB <-10 dB <-10 dB u-10 dB ≤-10 dB
RP Di OmDi SemDi Di Di Di
BW Few More than a u 20 143 u 570 600
(MHz) few
MC No Yes No Yes Yes No
Pol Linear Linear Linear Linear Linear Linear
Dim AP Length 27.8×10 156×70 24×27
(mm) 80×340 30.75
of the water bolus. In early modeling works of H&N applicator design, a cylin-
drical set up of antennas was considered in an infinite water bolus. The infinite
bolus was later modified to a closed water bolus in the HYPERcollar applicator
[72], with the bolus inflated with distilled water which was allowed to circulate.
Another alternative, the open water bolus system, has been used in Coaxial TEM
applicators [85]. These applicators are designed for treatment of deep-seated tu-
mours in the pelvic region, with the patient surrounded by water from their toes to
their upper chest. This approach provides optimal skin cooling, but without pres-
sure on the patient from the weight of the water bolus. The major disadvantage
of this concept is the limited access to the patient during the treatment, plus the
significant losses.
In today’s hyperthermia systems, water bolus is an integral part of antennas
applicators. This makes for easy positioning of the applicator around the target.
The predictability of water bolus shape is an extremely important factor affecting
treatment planning performance. In the ALBA 4D system, two water boli filled
with circulating distilled water are independently and remotely thermos-regulated.
They are placed between patient and antennas, for signal coupling and superficial
cooling [75]. In the new deep hyperthermia system by Pyrexar medical, BSD
2000 3D/MR, water bolus is an integral part of the applicator, with circulated
water providing temperature control for patient comfort [76]. In HYPERcollar3D,
predictability of the bolus shape was improved by splitting the water bolus into
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an inner flexible section attached to the body and a stiff outer section, where the
antennas are immersed [73]. This type of bolus can conform to skin contours.
2.3 Hyperthermia treatment planning
Hyperthermia treatment planning is defined as the process that begins with ob-
taining patient models and creating a set of quality indicators to maximize the
treatment quality using electromagnetic or thermal modelling [65][86]. Figure
2.5 illustrates the HTP process which begins with determining the geometry and
tissue properties of the relevant body part. The computed tomography (CT) or
magnetic resonance (MR) images of the relevant body part are segmented to give
an accurate, patient-specific model. The electrical and thermal properties are then
assigned to each tissue. In the next step, the power density (PD) and SAR dis-
tribution are computed using a combined model of the applicator and patient. In
addition to an accurate patient model, a precise applicator model is necessary for
quality of treatment planning. The applicator modelling includes the geometry
of the applicator and water bolus, plus electromagnetic modelling of the antenna
excitation and accurate meshing. After determining the PD, the temperature dis-
tribution can be predicted considering physiological conditions such as perfusion.
Finally, optimization methods are employed to maximize the power distribution
or temperature in the tumour while minimizing it in remaining healthy tissues.
This is done by defining several objective functions and determining the optimal
amplitude and phase settings for each antenna in the applicator.
Figure 2.5: Process of hyperthermia treatment planning using electromagnetic
simulation and optimization [86].
2.3.1 Numerical methods
Numerical techniques are used to solve the Maxwell equations and calculate the
internal electric fields within the body in hyperthermia treatment. The most com-
mon numerical techniques in electromagnetic modelling are finite difference time
domain (FDTD) and finite element method (FEM). These are used to compute the
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electromagnetic fields generated by antenna applicators. FDTD is formulated on
a Cartesian grid and discretises Maxwell’s equations in the time domain. In FEM,
the domain of interest is subdivided into small sub-domains and the field solu-
tion expressed in terms of a low-order polynomial on each of the sub-domains.
FEM is efficient in terms of the cell numbers, but mesh generation in this method
is time-consuming. On the other hand, FDTD is simple to perform and needs
less memory when dealing with large computational domains. Mesh generation
is also simple in FDTD and its parallel nature makes it suitable for acceleration
techniques.
In this thesis, majority of modellings and simulations have been carried out
in CST microwave studio with a transient solver as the solver of choice [87].
The ability to perform real-time domain simulations in this software enables us
to study the propagation of the field through the body. The finite integration
technique (FIT) is used to numerically solve electromagnetic field problems by
applying Maxwell equations to a set of staggered grids. Another important fea-
ture of this solver is delivering broadband frequency domain results, such as S-
parameters. These are useful in studying the reflected and absorbed power-loss
values using an antenna applicator. The calculation of fields at many frequen-
cies from just one simulation run also increases the computational efficiency. The
transient solver also applies advanced numerical methods for accurate modelling
of small and curved structures without extreme refinement of the mesh.
2.3.2 Patient modelling
Power density and temperature distribution are strongly dependent on 3D patient
modelling. Segmentation algorithms are required to delineate tissues from CT or
MR data and derive 3D patient models. The tissues are often manually segmented
by clinicians in a time-consuming process. Automatic segmentation tools have
been developed to speed this process up. An automatic segmentation algorithm
for CT images of the head and neck was recently presented and evaluated. This
algorithm improves reproducibility and reduces segmentation time [88].
Although current clinical practice in hyperthermia treatment is based on CT
images, magnetic resonance imaging produces higher levels of soft-tissue contrast
compared to CT. Current studies are investigating the use of MRI in addition to
CT for patient modelling in H&N hyperthermia treatment planning [89].
To facilitate the use of the dielectric data in Maxwell equations, it is better to
express their frequency dependence as parametric models. The characterization
of the dielectric properties of biological tissues was comprehensively reviewed
by Foster and Schwan [90]. In the literature review by Gabriel et al, dielectric
properties of biological tissues were extracted from the literature and presented in
graphical format [91]. These dielectric properties were characterized experimen-
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tally in the frequency range of 10 Hz to 20 GHz [92]. A parametric model was
then developed to describe the variation of dielectric properties as a function of
frequency [93]. In this model, the dielectric spectrum of a tissue is characterized
by three main relaxation regions and other minor dispersions. In its simplest form,
each of these relaxation regions presents a polarisation mechanism characterized
by a single time constant, τ . This is expressed by the so-called Debye expression,
as a function of frequency. Hurt also modeled the dielectric spectrum of muscle
to the summation of five Debye dispersions plus a conductivity term [94]. The
broadening of the dispersion could be accounted for by addition of a distribu-
tion parameter, called α . Accounting for the dispersion expansion, the Cole-Cole
equation was introduced as an alternative to the Debye equation [95][96]. There-
fore, multiple Cole-Cole dispersion is more appropriate to describing the spectrum
of a tissue:
εˆ = ε∞+∑ ∆εn1+( jωτn)(1−αn) +
σi
jωε0
(2.9)
In equation 2.9, εˆ is the complex relative permittivity, σi is the static ironic
conductivity, ε0 is the permittivity of free space and ε∞ is the permittivity at field
frequencies where ωτ  1.
Another important issue in hyperthermia treatment planning is uncertainty of
the dielectric and thermal modelling parameters. If these parameters have limited
precision, the uncertainty of the parameters affects the power and temperature
calculations. Dealing with these uncertainties is necessary if there is to be a robust
system design. In a study by Greef [97], the role of dielectric and combined
dielectric and perfusion uncertainty on optimization was investigated by means of
HTP for six different systems: 70 MHz AMC-4 and AMC-8, 130 MHz version of
AMC-8, a three-ring AMC-12 system, the BSD SigmaEye applicator and a dipole
applicator of 18 channels. The impact of dielectric uncertainty on optimization
was found to depend on the number of channels/antennas in the system. The
optimization results showed greater sensitivity of the optimization to dielectric
uncertainty when the number of channels increased. Considering the increased
complexity of a system with more channels, AMC-12 was found to be the best
compromise between heating efficiency and robustness. The optimisation method
of this study was temperature-based. In the following sections, power-density-
based and temperature-based optimisation techniques in HTP are explained in
more detail.
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2.3.3 Power-density-based optimisation
In the most common type of deep hyperthermia applicators, the phased arrays,
focusing into the target can be achieved by constructive wave interference of the
electromagnetic fields radiated by antenna elements. In this process, hotspots
(which are often caused by electric field maxima at boundaries with high dielec-
tric contrast) need to be minimised. This is usually done by different optimiza-
tion methods, such as the generalized eigenvalue method [98][99], genetic algo-
rithm [100] or particle swarm optimization followed by line search [101]. While
the generalized eigenvalue methods are fast, Genetic algorithms (GA) are usually
slower and can not find a globally optimal configuration. However GAs are able to
find settings less sensitive to antenna-steering uncertainties [86]. Particle swarm
optimization is used when more flexibility in the formulation of the optimization
function is needed. This optimization has shown to be effective in clinical imple-
mentation [101].
The optimization process begins after calculation of the electric fields. In the
optimization of the power density (PD) or specific absorption rate (SAR), the
amplitudes and phases of the sources are computed to give high PD/SAR in the
target and low PD/SAR in healthy tissues. In a phased array of N antennas, the
SAR distribution at a voxel r is:
SAR(r) =
σ(r)
2ρ(r)
|
N
∑
i
E(r)iVi|2 (2.10)
where SAR is the power absorbed per unit mass at the voxel r, E(r)i is the E-
field for antenna i, σ (r) and ρ(r) are conductivity and density at position r, and the
vector V is a complex vector showing the amplitudes and phases of each antenna.
In 1991, Sullivan presented a mathematical method for treatment planning in
deep regional hyperthermia using the Sigma 60 applicator [102]. To accelerate
a relatively computationally intensive optimization, he took advantage of the su-
perposition of E-fields while dividing the whole computational domain into four
quadrants. He used the impulse response method, in which one computer run was
enough to calculate the E-fields at frequencies of interest. In this method, the ra-
tio of the average SAR in the tumour to the average SAR in the body was used to
quantify the output. Based on the calculated SAR ratio, the amplitudes and phases
of the antennas were manually changed by the operator until the best SAR ratio
was found.
Another method of optimization is the generalized eigenvalue method. This
has been used as a fast optimization method to find amplitudes and phases of
phased arrays in regional hyperthermia [99]. In this method, based on the basic
equations for the electric field, power and temperature distribution, appropriate
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objective functions are defined for optimization of power density or temperature
distribution. The function for optimizing power density was defined as the quo-
tient of the energy absorbed in the tumour region to the energy absorbed in healthy
tissues. Maximizing this function leads to a solution of a generalized eigenvalue
problem. Bardati carried out SAR optimisation by maximizing the SAR in the
tumour and minimizing it in healthy organs [98]. The best array feed for each tar-
get (tumour/healthy tissues) was found by solving an eigenvector problem defined
for that target. The optimal excitation setting resulted from a trade-off of the best
array feeds.
In the work by Siauve et al. [100], a genetic-algorithm method was used to
optimise amplitudes and phases of n antennas in the applicator and consequently
to optimise the resulting SAR distribution. In this context, the genetic-algorithm
method followed the principles of evolution through natural selection to maximize
the defined objective functions. Six different SAR-based objective functions were
evaluated and compared with each other in terms of the power density value inside
the tumour. The genetic algorithm in this work was based on a finite element
formulation.
2.3.4 Temperature-based optimisation
A temperature-based optimisation is usually based on optimisation of power de-
position before calculating of the temperature distribution. The inclusion of non-
linear thermal models means that extensive numerical simulations are required for
the optimisation to be carried out. The common method for thermal modelling in
hyperthermia treatment planning is Pennes’ bio-heat equation, (PBHE)[103]:
cρ
∂T
∂ t
= ∇.(ktis∇T )− cbWb(T −Tart)+P (2.11)
where c is the specific heat capacity, ρ is the tissue density, T is the tem-
perature, t is the time, k is the thermal conductivity, Wb is the volumetric blood
perfusion and Tart is the local arterial temperature. The deposited power density
by antennas P(Wm−3) is calculated from the total E-field distribution. Assign-
ing different thermal properties to different tissues is used to model the hetero-
geneity in tissue properties. Heat transfer between large vessels and tissue and
direction of blood flow are not considered in this model, which can lead to in-
accuracies in temperature evaluation. The most common numerical method for
implementing the PBHE is based on the FDTD method. Since the PBHE is an
approximate model, several modifications have been suggested for PBHE consid-
ering temperature-dependent non-linear effects on thermal tissue properties. One
of these modifications is to use temperature-dependent parameters. In [104], a
temperature-dependent blood perfusion model is used to improve the classical
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bio-heat term. As with blood perfusion, the reason for choosing temperature-
dependent tissue parameters is that, when heating tissues up to 41-43 ◦C, the blood
flow in normal tissues increases significantly whilst decreasing in the tumour. In
the other modified PBHE model, effective conductivity, ke f f is incorporated as a
function of perfusion and an empirical factor [105]. In this work, comparison of
different bio-heat models with the measurement results showed that, in the model
with effective conductivity, conduction was found to be an important heat removal
mechanism.
To model discrete vasculature, a complex thermal method (DIVA) has been
developed which describes vessels as 3D curves [106]. Although this model has
been validated in isolated animal organs, complexity in modelling 3D vascular
networks results in long computation times. This makes the method impracti-
cal for clinical application. New methods have been developed for fast calcula-
tion of the steady-state temperature distribution and temperature-based optimiza-
tion, based on the DIVA model and suitable for regular use in treatment planning
[107][65]. While calculation of the steady-state temperature distribution in the
original DIVA model took about 3.3 hours, it took about 1.5 hours with the fast
method presented in [107]. Optimisation results with discrete vasculature mod-
elling were also compared to the optimisation results from Penne’s bioheat equa-
tion. This resulted in variation of antenna powers by a factor of 2, demonstrating
the importance of taking into account the discrete vasculature model during the
optimisation.
Temperature-based optimisation techniques to find the optimal phases and am-
plitudes of phased-array systems are more clinically suitable than power-density-
based optimization. This is because temperature-based optimisation techniques
take into account parameters such as thermal conduction and perfusion in the op-
timisation process. In a study by Greef [108] (analysing the effect of perfusion
uncertainty on optimisation in HTTP), the performance of four power-based opti-
misation methods was compared with a constrained temperature-based optimisa-
tion, using T90 as the measure of thermal dose. Temperature-based optimisation
results showed 1◦C difference from the optimum solution, while deviations for
the SAR method were up to 2.9◦C. It was concluded that temperature-based tech-
niques are preferable to SAR-based alternatives.
Quality indicators
The quality of a hyperthermia treatment is strongly affected by SAR in the target
and by SAR peaks outside the target (known as hotspots). The SAR values in the
target and the hotspots are therefore very important in analysing SAR distribu-
tions. While the SAR in the tumour needs to be maximized to raise the tumour
temperature, hotspots have to be minimized to prevent patient discomfort during
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the treatment.
A literature survey by Canters et al. evaluated various quality indicators in
terms of their correlation to the temperature increase in the tumour [109]. T50target ,
the median target temperature, was used to evaluate the SAR indicators for the
purposes of characterisation and optimisation.. The reason for choosing T50target
was its insensitivity to any temperature deviations which might have disturbed the
evaluation. The indicators which were most useful for characterisation had a close
correlation with the target temperature (T50target). This means that a high value in
these quality indicators equates with a high target temperature. Moreover, a suit-
able SAR indicator which is used as the goal function of the optimisation should
lead to an optimal T50target . Based on these evaluations, two indicators were
found to be most appropriate. The first, SARhs−targratio, is defined as the ratio of
the SAR exceeded in 1% of a region’s volume and the median target SAR. This
objective function, which is used to compare the highest SAR values in healthy
tissues to the tumour SAR, is the most useful for hotspot reduction and optimisa-
tion procedure. The second indicator, SARtarg, is defined as the averaged SAR in
the tumour and is most useful in comparing absolute SAR values.
To evaluate the quality of SAR distributions, the hotspot quotient ratio (HTQ),
similar to SARhs−targratio, was defined in Canters [110]:
HTQ =
SAR(V1)
SARtumour
(2.12)
Here SAR(V1) is the average SAR in the first percentile of the highest SAR
values in healthy tissues and SARtumour is the average SAR in the tumour. In this
study, the effect of patient position variations and inaccuracies were evaluated
in context of SAR distribution robustness. For ten patient models tested in this
work, HTQ values varied between one and five. HTQ has also been used as the
goal function for optimizing SAR distribution in hyperthermia treatment planning
[111]. In [111], the potential of SAR steering in VEDO software was demon-
strated by analysing the first treatment using the HyperCollar. In the software, the
relative amplitudes and phases of each antenna were optimised to minimize the
goal function, HTQ. As the goal function, HTQ has been employed to maximize
the SAR in the tumour and minimize the SAR in healthy tissues.
It is known that time and temperature have a direct effect on the rate of cell
killing during hyperthermia treatment. To date, various methods have been sug-
gested for expressing the time-temperature data in a common unit, allowing com-
parison of different heating regimes. This is particularly important for clinical
hyperthermia, where temperature distribution is not uniform spatially and not sta-
ble temporally [112]. In [112], basic concepts relating temperature and time to
cell killing and tissue damage are presented.
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Thermal dosimetry measures that are most often reported in the literature in-
clude: T90, T10 and T50 as temperature parameters; cumulative time above 40◦C,
41◦C, 42◦C and 43◦C as time parameters; cumulative number of equivalent min-
utes at 43◦C (CEM43); cumulative equivalent minutes at 43◦C at the T90 temper-
ature as thermal dose parameters [113]. Here, T90 is defined as the tissue temper-
ature exceeded by 90% of all temperature measurements, T50 is the temperature
exceeded by 50% of the measured points in the tumour and T10 is the temperature
exceeded by 10% of the measured points in the tumour. In clinical application
of the thermal isoeffect dose (TID) concept, different heating protocols for differ-
ent times at different temperatures are converted into equivalent minutes at 43◦C.
For several heat treatments in the clinic, the TIDs for each can be added to give
a cumulative number of equivalent minutes at 43◦C, CEM43. For example, the
threshold for thermal damage in a sensitive brain in terms of EM43◦C is about
30-50 minutes while, for more heat-tolerant muscle tissue, this threshold is 240
minutes.
2.3.5 The time-reversal method
Time reversal method is based on the time-symmetric property of the wave equa-
tion in a nondissipative medium. It was first introduced by Fink et. al for ul-
trasound [114] and later for electromagnetics by Trefna et. al [115]. The time-
reversed process starts with the radiation of a pulse from a point-like source at
position r0. A cavity surrounds the source at which the time dependence of field
components are measured. In electromagnetics, time-reversed wave fields inside
the volume of the cavity are obtained by time-reversing the E-fields and radi-
ating them from the cavity surface. This corresponds to the transformation of
E(r, t)→ E(r,T0− t). These time-reversed fields are back-propagating by means
of monopolar or dipolar sources covering the surface [116]. Considering the
source function as a Dirac distribution, the time-reversed electric field is given
as:
ETR(r, t) ∝ G(r0,r,−t)−G(r0,r,+t) (2.13)
where G(r0,r, t) is the causal and G(r0,r,−t) is the anticausal Green’s func-
tion. The interference of the converging and diverging waves results in a focal
spot with a maximum size of λ/2. The focus size limit results from the Fourier
transform distribution of the E-field, which is proportional to the imaginary part
of the Green’s function:
G(r0,r,ω) =
e− jk‖r−r0‖
4pi‖r− r0‖ (2.14)
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and
ImG(r0,r,ω) ∝
sin(k‖r− r0‖)
‖r− r0‖ , (2.15)
where k is the wave number.
(a) (b)
Figure 2.6: The principle of the time-reversal method. (a) The recording step (b)
The time-reversed step.
The time reversal theory can be used to focus the power absorption in the tu-
mour volume. The advantage of time reversal in hyperthermia treatment planning
is the speed of the method and its suitability for pulsed and continuous excitation.
As explained in the HTP section, for general optimization methods, calculating
the EM fields of all the antennas in the patient model is necessary to find the opti-
mal amplitudes and phases for the antennas in HTP process requires. This process
is very time-consuming due to the computation time for a single iteration. Unlike
the traditional optimization methods, there is no need to calculate the E-fields
of all the antenna elements in the applicator. To minimize power absorption in
healthy tissues, it is necessary to incorporate hotspot reduction techniques in the
treatment planning process.
In the first step, the modelling part, one or more sources are placed in the
tumour volume. The optimum position of the virtual source is where the max-
imum tumour coverage can be achieved. The optimum position depends on the
size and position of the tumour plus the frequency of treatment, as shown in Paper
II. The simulated E-fields are recorded by electromagnetic models of the antenna
elements. In the second step, the treatment, the antenna elements transmit the
recorded field in time-reversed order. The time-reversed signals are then focused
on the position of initial sources in the tumour due to the time-symmetric property
of the wave equation in a lossless medium.
The time reversal focusing method has been evaluated for hyperthermia treat-
ment planning of 2D models of the neck and breast by our group [115]. The
method was implemented by 2D FDTD algorithm and the 2D models immersed
in a background of water. The performance of the focusing method was evalu-
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ated by quantifying the power absorption distribution in tumour areas, in terms of
several parameters. The parameters studied were: the type of antenna excitation,
the number of antennas in the applicator and the frequency. Although the 2D time
reversal method worked well for 3D predictions [81][115], there were limitations
when modelling more than one ring applicator in 2D modelling. This limitation
can be obviated by a 3D implementation of the time reversal method using the
FDTD algorithm as presented in Paper II.
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The applicator design
This chapter discusses our approach in designing a compact UWB antenna ele-
ment for hyperthermia applicators and the design process of hyperthermia appli-
cators. An important objective is that the designed applicator should be able to
heat deep as well as superficial tumours. One way of achieving this is to build
in the capability to switch between multiple frequencies in the desired frequency
range. This ability enables us to reach centimeter-scale spatial resolution by us-
ing higher frequencies and reach high penetration depths at lower frequencies.
Another important design criterion is to use a large number of antennas. This
requires the antennas to be small. The latter is also beneficial in controlling the
focusing capability of the system that is designed. As discussed in section 2.1, the
antenna elements in our applicator should be designed to have wide-band perfor-
mance with low reflection coefficients, high penetration ability and high effective
field size over the whole band. Moreover, the antenna elements should be com-
patible with the magnetic resonance device, which is required for non-invasive
thermometry [117].
3.1 Conceptual design of the antenna element and
water bolus
The antenna design discussed in this thesis is mainly based on the Bow-Tie an-
tenna, with wide-band performance and stable radiation characteristics across the
frequency range of 430-1000 MHz. The reason for designing the antenna in this
frequency range is that it has been shown to be efficient in treatment of H&N tu-
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mours [81][115]. Moreover, the self-grounded Bow-Tie design was selected due
to its directional radiation pattern over a wide frequency band, plus its small size.
To reduce the size of the single antenna, it is immersed in water. The specifically
designed shape of the water bolus plays a significant role in improving the heat-
ing efficiency. In addition to the limited-size water bolus of the antennas, an extra
water layer between the antennas and the patient is used for direction of electro-
magnetic energy into the body and for cooling the patient’s body surface during
treatment. More details on design and analysis of the antenna are presented in
Paper I.
The sensitivity analysis of the antenna performance versus the size of the water
bolus was further investigated by scaling the conical AWB, but keeping the size
of the antenna and the dielectric layers fixed. The performance of the antenna
was evaluated in the same setup as presented in Figure 4.1(b), by finding the S11
parameters versus the frequency. The calculated reflection coefficients, or S11
parameters for different AWB sizes are shown in Figure 3.1. Here, we scaled
the AWB while keeping its height constant at 25 mm. The smallest and largest
simulated AWBs are shown in Figure 3.2. The results presented in Figure 3.1
are summarized in Table 3.1, in terms of the resulting bandwidths when S11 ≤
-10dB. As shown in the table, the lowest obtained operational frequency is about
440 MHz for a scale factor of 1.2, while the maximum obtained frequency is
about 920 MHz for a scale factor of 0.84 . This showed that the sensitivity of the
S11 variation relative to the variations in AWB size is not significant. The other
important conclusion was derived by finding a relationship between the length of
the dipole and the operational frequencies of the antenna for different AWB sizes.
As shown in Figure 3.1, the lower operational frequencies for K = 1, 1.2, 1.4, 1.8,
2.4 and 3.4 vary between 440-480 MHz. The wavelengths at this frequency range,
considering water as the dielectric medium, vary between 70-77 mm. Moreover,
the total length of the dipole radiating arms is about 40 mm. This shows the dipole
length to be approximately equal to half the wavelengths at the lower operational
frequencies of the antennas for different K values.
3.2 Head and neck applicators
Due to differences in anatomy and dimensions of the head and neck, two ex-
changeable applicators were developed; one for treatment of head tumours and
one for the tumours in the neck. Treating neck tumours (such as laryngeal tu-
mours) with a large applicator could result in the appearance of hotspots in other
tissues, such as the chin or shoulders. The presence of hotspots in these regions is
due to the transition between bone, which has low conductivity, and other tissues
with higher conductivity values. Since the neck is smaller, fewer antennas ele-
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Figure 3.1: S11 variation versus different cone size, the height of the cone is fixed
at 25 mm.
Figure 3.2: From left to right, the largest and smallest simulated AWB.
Table 3.1: -10dB bandwidth of the Bow-Tie antenna immersed in conical water
boli of different size. K shows the scaling factor for the top and bottom
cone diameters.
BW (MHz)
K = 1 [460 - 870]
K = 1.2 [440 - 870]
K = 1.4 [450 - 860]
K = 1.8 [480 - 800]
K = 2.4 [470 - 820]
K = 2.8 [470 - 860]
ments will suffice. The applicator consists of 10 antennas of adjustable diameter.
In designing the head applicator, we must take into account the larger size of the
head and the presence of complex anatomical structures.
By investigating the effect of the number of antennas and the radius of the
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array relative to the neck size on a cylindrical muscle phantom, it was found that
10 antennas in a circular array of 100 mm-radius provided the best focus in the
phantom. Thus, the optimal neck applicator consists of 10 antennas arranged in
one ring. The same investigation was carried out to find the optimal number of
antennas and size of the head applicator in cylindrical and elliptical muscle phan-
toms. This resulted in an elliptical applicator consisting of 16 antennas arranged
in two rings and with radii of 104 mm along the X axis and 114 mm along the Y
axis. In both applicators, water boli of thickness 1-2 cm are placed between the
body and the applicator.
(a) (b)
Figure 3.3: The applicators for (a) head and (b) neck tumours shown on anthro-
pomorphic phantoms of head and neck.
3.3 Brain applicator
As discussed in section 1.2, hyperthermia in addition to standard modalities has
been shown to enhance the treatment outcome of brain tumours. To apply hy-
perthermia, applicators capable of heating the brain tumours are required. The
principle of annular phased arrays can be applied to the design of intracranial ap-
plicators. However, applicators of a helmet-shaped design are more beneficial due
to their higher degree of tumour coverage. This is because extra radiation reaches
the tumour from a third dimension.
An initial design of the head applicator was presented in [118] for treatment
of intracranial tumours in children. The helmet-shaped applicator consisted of 15
antennas in two rings of eight and six elements, with one antenna located on top
of the head. As shown in figure 3.4, all the antennas were tilted according to the
head shape. The surface water bolus consists of three strips of 7 cm wide and
2 cm thickness. Although the SAR distributions obtained for different tumours
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were favorable, the T50 of 38◦ was somewhat disappointing for treatment of large
tumours such as medulloblastomas [118]. There are two alternative solutions in
tackling this challenge. The first is to decrease the operational frequency band of
the antennas and improve the penetration depth of EM waves. The second is to
substantially increase the number of antennas used and is the approach followed
in Paper III. This paper compares the performance of three helmet-shaped appli-
cators, for heating large, deep-seated brain tumours in children.
Figure 3.4: Initial design of a child head applicator consisting of 15 antennas.
As shown in Paper III, the power deposition in the tumour is proportional to the
number of antennas in the applicator. An initial design was therefore considered,
of a helmet-shaped applicator with 50 Bow-Tie antennas. These antennas were
placed over a 10 mm water layer, surrounding a spherical phantom of radius 100
mm, approximating the size and shape of a child’s head (see Figure 3.5(a)). The
phantom had tissue properties of brain grey matter and the dielectric properties of
the biological tissues were extracted from the IT’IS database [119]. The antennas
employed in the applicator were regular Bow-Tie antennas immersed in reduced-
size conical water boli with a wide-band performance over 500 MHz-1 GHz.
The heating capability of hyperthermia phased arrays have been investigated,
in terms of power to the tumour and other figures of merit, in the work by Bardati
et. al. [120]. This work assumed that each antenna is limited to a maximal nom-
inal power. Under such constraints, they proposed new methods to maximize the
power-to-tumour ratio and heating efficiency. To characterise the heating perfor-
mance of the applicators, we took a different approach by using a new algorithm
to search through the whole phantom model (head/brain) and find the easiest/most
difficult place to heat. This information allows us to know if a specific applica-
tor design is able to heat a tumour at a specific position in the head. The search
results in this algorithm are based on the value of hyperthermia quality indicators
aPA, RTMi and HTQ. In the current design, HTQ is considered as the basis of
our search results. As shown in Figure 3.5 (b), the algorithm goes through all the
voxels in the head, considering each voxel as a focus point. Using the calculated
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E-fields of the antennas in the applicator at a specific frequency, the power-loss
density and specific absorption rate (SAR) are computed. Finally, by computing
the quality indicators at each voxel, the easiest/most difficult places to heat in the
phantom were found.
(a) (b)
Figure 3.5: (a) Helmet-shape applicator with 50 antennas (b) Cross-section of the
phantom model discretized into voxels. Each voxel is considered as a
focus point in the search method.
Table 3.2 gives the coordinates of the easiest/most difficult places to heat in
the phantom at 500, 600, 700 and 800 MHz. The dimensions of the original tissue
matrix of the spherical head phantom were 200 × 200 × 200 mm3. To avoid
lengthy computation times, we decreased the resolution of the tissue matrix to 5
mm which resulted in a matrix of 40 × 40 × 40 mm3. In Table 3.2, the most
difficult places to heat are those with the highest HTQ and the easiest places have
the lowest HTQ values.
Table 3.2: Worst and best HTQ coordinates of 50 antennas obtained in a 40 × 40
× 40 mm3 head model. The centre of the phantom is located at the
point [20,20,20].
Frequency Worst HTQ coordinates Best HTQ coordinates
500 MHz [8, 20, 36] [20, 20, 20]
600 MHz [24, 17, 39] [6, 20, 20]
700 MHz [31, 20, 38] [20, 20, 20]
800 MHz [27, 16, 39] [20, 20, 20]
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Figure 3.6: The coordinates with highest (shown in green) and lowest (shown in
red) HTQ values found by using the search algorithm in the spherical
phantom surrounded by 50 antennas, Figure 3.5(a).
Table 3.2 shows that the points with high HTQs are closest to the top of the
phantom (the z-coordinate values close to 40 mm), while the points with lower
HTQs are close to the phantom centre (z-coordinate values close to 20 mm). The
position of these coordinates over a sphere of radius 20 mm is shown in Figure
3.6. The results presented in Table 3.2 show that the most difficult places to heat
vary spatially with different frequencies. This shows the potential of the multi-
frequency approach, which was the motivation for designing UWB antennas and
applicators in this thesis.
As a next step, the complex geometry of the head is taken into account by
using a realistic model of a child’s head containing medulloblastoma. The sagittal
plane of the head model as well as the antenna applicator are depicted in figure
3.7. The applicator design is different from the previous one in its helmet shape
and the use of two different types of antenna. The antennas used are the proposed
SGBT, designed to work at two operational bandwidths. The applicator consists
of 23 antennas with 9, 9 and 5 antennas in the first, second and third rings re-
spectively. The antennas in the first ring operate at a lower frequency band and
therefore have greater dimensions. The operational frequencies considered for
the antennas in the first ring were 350 and 400 MHz. For the conventional SGBT
antennas designed for the frequency band of 450MHz-1GHz, 450, 500 and 550
MHz were considered as excitation frequencies. After calculating the E-fields of
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all the antennas at selected frequencies, the search method was implemented to
find the easiest/most difficult places in the head, in terms of the computed HTQ
values.
(a) (b)
Figure 3.7: (a) Model of a child’s head with a medulablastoma shown in black.
(b) A helmet-shaped applicator for a child’s head with 23 antennas.
Figure 3.8: Worst HTQ places for 23 antennas obtained in a 44 × 52 × 56 mm3
head model. The figure shows locations for six different frequency
combinations.
Figure 3.8 shows the most challenging locations for intraranial heating inside
the child’s head model at six different combinations of frequencies, representing
the excitation of the scaled and regular antennas. The size of the tissue matrix
including the surrounding water and air was 220 × 260 × 280 mm, which was
down-scaled to 44 × 52 × 56 mm by a resolution of 5 mm. As shown in the
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figure, the most difficult places to heat are located deep inside the head and quite
close to the tumour volume. Evaluating the performance of this applicator at 350
and 500 MHz as the frequencies for the scaled and conventional antennas resulted
in an HTQ value of 3.84, for the average tumour radius in the head model of
about 3 cm. Likewise, the previous applicator with 50 antennas resulted in an
HTQ value of about 2 to heat a similarly sized and positioned medulloblastoma
in the homogeneous model. Since the calculated HTQ values indicate possible
challenges to achieving suitable tumour temperatures, it is anticipated that further
improvements to the current applicators will be achieved by optimising the an-
tennas positions within them. More details regarding the optimisation of antenna
positions are presented in Paper IV.
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Summary of results
4.1 Paper I
This paper presents a novel concept for a self-grounded Bow-Tie-type antenna
design. This is intended for use as the basic element of a phased-array appli-
cator. The UWB operation in the frequency range of 0.43-1GHz is achieved by
immersing the antenna in water bolus. The radiation characteristics are improved
by appropriate shaping of the water bolus and by including dielectric layers on
top of the radiating arms of the antenna.
To determine the most appropriate design, we use a combination of perfor-
mance indicators representing the most important attributes of the antenna: UWB
impedance matching, transmission capability and effective field size. This com-
bination can serve as design criteria for antennas for near-field application.
Among different antenna water bolus (AWB) shapes, the optimal shape was
obtained by evaluating the resulting reflection coefficient and SAR distribution
of the antenna in a muscle phantom. The conical-shaped WB with optimal PLD
values and S11 antenna parameters was selected.
The improved antenna performance (brought about by adding dielectric layers
to the Bow-Tie radiating arms) is demonstrated in terms of the surface current
density, E-field distribution and the reflection coefficients of the antenna, with
and without dielectric layers. It is seen that, in presence of dielectric layers, higher
surface current densities on the antenna arms lead to improved energy propagation
into the muscle phantom. Lower absolute values of the reflection coefficient were
also observed, with the added dielectric layers on the Bow-Tie radiating arms in
41
CHAPTER 4. SUMMARY OF RESULTS
(a) (b)
Figure 4.1: (a) Model of the self-grounded Bow-Tie antenna and (b) size parame-
ters for the antenna water bolus.
the conical shape AWB.
In experimental validation of the antenna, the measured reflection coefficients
of -9 dB or better are comparable with the simulation results in the frequency
range 0.46 - 1 GHz. Finally, the heating ability of the antenna was evaluated by
measuring the temperature distribution in the muscle phantom when the antenna
was supplied with 10 W of power for 10 minutes. The maximum temperature
increase measured by fibre optic probes was 6.5◦C.
The compatibility of the antenna with an MR scanner was investigated inside a
1.5 Tesla MR scanner. Magnitude MR images of the antenna covered by WB bags
show that the SMA connector with ferromagnetic material causes major image
distortion. Therefore, the antenna is MR-compatible if the connector is replaced
by non-magnetic one.
4.2 Paper II
This paper examined the impact of antenna numbers on the operational frequen-
cies in an annular phased array for H&N. As a first step, the ideal frequency as
a function of antenna numbers is investigated. Another question addressed is the
optimum position of the virtual source in the recording stage of the time-reversal
method.
Using the time-reversal method as the means of focusing, the antennas set-
tings were determined in the range of 400-900 MHz. The antennas surrounded a
homogeneous cylindrical phantom of muscle enclosing a spherical tumour. The
analysis was performed for 4-48 number of antennas and tumour positions rang-
ing from the surface to the centre of the phantom. The tumour was considered
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using the same dielectric properties as the phantom and power loss density values
were computed in the phantom area. The analyses were performed in the mid-
dle cut-plane of the phantom (2D), to prevent long computational times due to
the high number of antennas. The optimum frequency range for each tumour po-
sition and number of antennas was determined based on the calculated aPA, the
average power absorption ratio and the 50% tumour coverage. For each tumor
position and number of antennas, a frequency range with a high aPA value and
approximate 75% of TC50% was selected.
In the second part of the paper, we carried out analyses in a 3D model of an
elliptical muscle phantom enclosing a spherical tumour with the same dielectric
properties as the surrounding phantom. A head applicator with 16 modified Bow-
Tie antennas was considered. Based on our previous analyses, the optimum fre-
quency range for 16 antennas was between 400-500 MHz for all tumour positions.
The 50% tumour coverage was used to evaluate the heating efficiency at 400 and
500 MHz, with the tumour position varied along the Y-axis of the phantom, from
surface to centre. For all the simulated frequencies, the maximum coverage for
the tumour closest to the phantom centre was achieved at tumour-centre position.
Finally, the optimum position of the VS was studied in realistic tumour models,
with the tumour located deep inside the head. The analysis of the tongue tumour
showed agreement with simple analysis results of the elliptical phantom.
4.3 Paper III
In Paper III, a laboratory prototype of an UWB hyperthermia applicator was pre-
sented and tested for treatment of tumours in the head and neck region. In the
neck applicator, 10 self-grounded Bow-Tie antennas were arranged in two rings.
The main reason was to decrease the smallest possible diameter of the array. Also,
the diameter of the neck applicator was adjustable between 180 and 220 mm. As
designed in Paper I, each antenna was placed inside a conical enclosure filled
with distilled water. An extra layer of circulated distilled water was used to fill
the space between the patient and the applicator to ensure matching and provide
the necessary cooling of the surface. In this experiment, a thin single-inlet-single-
outlet plastic bag was used as the water bolus. All antennas in the applicator
operated in the frequency range of 450 MHz and 900 MHz.
The focusing capability of the applicator intended for treating neck tumours
was tested on a homogeneous muscle phantom at 500 MHz. The phantom was
located centrally inside the applicator. Both phantom and water bolus had initial
temperatures of 20◦C, i.e. room temperature. Prior to the experiments, the phan-
tom was cut in its centre plane in order to capture thermal images using an IR
camera. The setup of the experiment is shown in Figure 4.2.
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Figure 4.2: Measurement setup shows the muscle phantom surrounded by water
bag and applicator.
Two tumor positions were investigated: one in the centre and one at side of the
mid-transverse plane of the phantom. The time-reversal cavity was used to deter-
mine the amplitude and phase settings of the antennas. In the first experiment, the
aim was to focus in the centre position. The temperature distribution in the central
plain of the pre-cut muscle phantom was captured by IR camera using a 10-minute
exposure. A 12◦C temperature increase was obtained at the centre position. For
the second experiment, the focusing was in one side of the central plane. Using
the new setting at a total power output of 25 W, a maximum temperature increase
of 8◦C was achieved in this side position after 10 minutes radiation into the phan-
tom. As shown in Paper III, the temperature images indicated agreement between
the planned and measured focal spots, with an acceptable temperature increase in
these areas.
4.4 Paper IV
In this paper, we move away from a classical, annular-phased array design to
novel, helmet-shaped applicators for dedicated intracranial heating. We use the
SGBT from Paper I as antenna elements in the applicators. The dimensions were
scaled up by a factor of 1.6 so as to cover even lower frequencies. However, to
facilitate the use of more antennas, the dimensions of the water bolus in the anten-
nas were significantly reduced. This resulted in the operational frequencies over
314-600 MHz and 500 MHz-1 GHz respectively. First, we studied the effect of
increasing the number of antennas on the average power loss density in the tu-
mours. These were tumours located deep in the brain, at the centre and in one
instance in a non-central position in a homogeneous spherical phantom with the
dielectric properties of grey matter. Our simulation results revealed that increas-
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ing the number of antennas, regardless of their frequency range, always resulted
in higher average PLD in tumours. Moreover, heating the tumour in the centre
position was easier than the non-central positions in all the applicators.
In the next part of the paper, three virtual applicators with 15, 26 and 58 Bow-
Tie antennas were evaluated in terms of the calculated tumour coverage, aPA and
RTMi values over the frequency range of 400-900 MHz. The results obtained in-
dicated that applicators with more antennas produced significantly higher tumour
coverage than ones with fewer antennas. This applied to both tumour positions
studied. Moreover, using more antennas at higher frequencies was found to be
more beneficial in increasing the power absorption in tumours than using fewer
antennas at lower frequencies. For larger tumours, lower frequencies resulted in
less absorbed power in healthy tissues.
4.5 Paper V
In this paper, we developed a novel method to find an optimal positioning of the
antenna elements within an antenna applicator to heat a tumour of a given size
and position. The applicators where the antennas were positioned was the helmet
structure introduced in paper III. The initial head model was a spherical, homo-
geneous phantom with dielectric properties of brain grey matter surrounded by
a thin water layer. To evaluate the convergence of the algorithm to the optimal
solution, dipole antennas immersed in water bolus were used initially and Bow-
Tie antennas were used later. The optimisation was verified with reference to the
constraints on overlapping antennas. In the main part of the paper, the antenna
placement was optimised to achieve the most favorable SAR distribution in a re-
alistic model of a 13-year-old child with medulloblastoma.
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Conclusion and outlook
This thesis has presented developments towards an optimal microwave hyperther-
mia applicator for treatment the head and neck as well as brain tumours. Two
of the main components in a hyperthermia system have been studied: the hyper-
thermia applicator and hyperthermia treatment planning. Papers I and III have
presented the design and experimental verification of the single antenna element
and the H&N applicator. Papers II, IV and V were mainly based on the numerical
modellings, simulations and optimisation, using the principle of the time-reversal
method.
In the first paper, a wideband antenna was developed for use as the radiat-
ing element of the phased array hyperthermia applicator. The typically large,
narrow-band antenna elements in hyperthermia applicators were replaced by a
small, wide-band antenna. This meant that we could incorporate large number
of antennas in the applicators which resulted in high power deposition values in
the tumour, as shown and presented in Paper III. Moreover, the wideband perfor-
mance provided the capability to switch over frequencies which, in turn, enabled
the heating pattern of the antenna to be adapted to a specific target. The antenna
was verified experimentally on a homogeneous muscle phantom. Moreover, the
test of our single antenna in an MR scanner device showed its compatibility for
future thermometry measurements. However, adaptation is needed to cope with
the high voltage and power of an MR scanner. One method is to use high-voltage
non-magnetic trimmers, placing a cable trap in the feeding cable of each antenna.
This can enforce large impedance on the coaxial cable [83][84].
Paper II focused on hyperthermia treatment planning and a time-reversal method
was used to find the amplitudes and phases of the antennas in the applicators. This
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paper proposed a selection scheme for frequency and virtual source positioning in
the time-reversal method. The results obtained, in terms of number of antennas
and frequency, showed that lower operational frequencies were appropriate for ap-
plicators with fewer antennas, while higher frequencies were optimal when there
were more antennas and for superficial tumours. Moreover, in the analysis to
find the optimum position of the virtual source, the position of the tumour was
found to be a crucial factor. A number of simplifications were made to this pro-
cess. Firstly, the modeled phantom was homogeneous meaning that the presence
of many tissues around the tumour was ignored. Also, the tumour was represented
as a spherical homogeneous volume, which is not the case for real tumours. Also,
the absence of a source with a spherical radiation pattern in CST software meant
that we had to model the virtual source as a small, discreet port.
Paper III presented and tested the laboratory prototype of the hyperthermia
applicator for treating head and neck tumours. Although the experiment sim-
ply proved the functionality of the time-reversal method in practice, there were
a couple of issues requiring further consideration in future work. Firstly, two
interchangeable hyperthermia applicators have been designed and manufactured
for treatment of the head and neck tumours. To adapt the applicator diameter to
the patient’s neck or head size, antennas must be moved radially for each patient,
which can be an unwieldy exercise. This means the water bolus between the pa-
tient and applicator needs to be redesigned for each patient, which demands a
stable, reproducible water bolus design. Secondly, the water bolus in the experi-
ment was a single-inlet-single-outlet water bag which was not an integral part of
the applicator. This can result in the presence of an air gap in front of the antennas,
thus causing mismatch.
The last two papers were focused on hyperthermia applicators for treating
brain tumours. Paper IV presented helmet hyperthermia applicators for heating
deep-seated brain tumours in children. It also investigated the effect of large num-
bers of antennas and low frequencies on the heating efficiency of the applicators.
As with Paper II’s presentation of phased array applicators, increasing the num-
ber of antennas resulted in higher average PLD in the tumour and more tumour
coverage. Moreover, lower frequencies were found to be more efficient (in terms
of treatment quality) at heating larger tumours than higher frequencies. To show
that the simulations carried out were reasonable in the homogeneous phantom, di-
electric properties of the phantom were compared and found to be similar to those
of an averaged brain model. In particular, the σ was less than 8% lower than the
one in the averaged homogeneous brain model. Limitations we may face in this
regard arise from introducing a helmet applicator to the clinic with a large number
of antenna elements (50 for example). Antenna positioning, the degree of flexibil-
ity to move or rotate over the small surface of a child’s head and cross-coupling
between the adjacent antenna elements are some of the possible limitations.
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In the last paper, the optimal positioning of antennas was investigated for heat-
ing deep-seated brain tumours. The optimisation method was initially verified on
a homogeneous spherical phantom and then carried out using a realistic model
of a child’s head. Since the optimisation was based on finding the best value of
hyperthermia quality indicators, the computation of E-fields prior to the optimisa-
tion was unavoidable. However, in an applicator with a large number of antennas,
this calculation is computationally expensive. Consequently, the E-fields in all
the optimisation were obtained by doing a rotation of one or two pre-calculated
E-fields, followed by interpolation. This resulted in approximated E-field values.
Moreover, to avoid long computational times, the resolution of all the 3D matri-
ces used was decreased. These factors may have introduced uncertainties into the
final optimisation results. More limitations may arise subsequently, when manu-
facturing the applicator. As one of these limitations, the size of the applicator must
be adapted to the head of each patient. In addition, different antenna settings are
required for each patient. Moreover, in optimising the antenna positions, a certain
flexibility in moving the antennas is to be expected. In designing a brain applicator
with a large number of antennas, the greater level of flexibility is accompanied by
greater systemic complexity. There is, nevertheless, scope to improve the heating
efficiency in an applicator design. One such improvement is optimising an appli-
cator consists of antennas with different frequency ranges. Another would be first
finding the most difficult places to heat in the tumour of a patient model and then
conducting the optimisation to achieve the best quality indicator for heating that
place.
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